Skip to content

Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain

Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00176163
Enrollment
240
Registered
2005-09-15
Start date
2005-08-31
Completion date
2009-05-31
Last updated
2010-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain, Fibromyalgia

Keywords

Fibromyalgia, Back pain, Behavior Therapy, Operant learning, Tetrahydrocannabinol

Brief summary

It is known, that a so called pain memory usually evolves in chronic pain syndromes which both aggravates the disorder and modifies the patients pain perception. Thus, the principal object of pain therapy is to delete this dysfunctional pain memory. The combination of medication, physiotherapy and psychological therapy seems to be the most effective treatment. This study investigates the effect of a concomitant Dronabinol medication (Cannabinoid) on the effectiveness of behavioral therapy. It is hypothesized that the combination of behavioral therapy and Dronabinol will be most effective in deleting the pain memory.

Detailed description

This study investigates the combination of operant behavioral treatment and Cannabinoid medication in patients with fibromyalgia and patients with back pain. It is well known that cannabinoids (THC) accelerate learning processes. It is assumed that the combination of both treatments may exert an synergetic effect. A low dose of THC is used, which ist not expected to have direct analgetic effects. The study also investigates genetic determinants of both disorders and the response to treatment, respectively. The patients will be randomly assigned to one of four groups: Behavioral therapy and Dronabinol, behavioral therapy and placebo, behavioral therapy only, standard medical therapy. Patients will attend 12 weekly group-sessions (6-8 patients) of behavioral therapy. Behavioral therapy sessions will include training in reducing pain behaviour and establishing active and healthy behaviour instead. There will be weekly medical safety visits, in which the patients receive medication and undergo a physical examination (blood and urine samples). Patients will be evaluated before and after behavioral therapy and will be followed for an additional 6- and 12-months phase. The outcome variables will be recorded by the use of interviews and questionnaires.

Interventions

BEHAVIORALOperant behavioral treatment; Drug: THC

Sponsors

Central Institute of Mental Health, Mannheim
CollaboratorOTHER
University of Mannheim
CollaboratorOTHER
Academic City Hospital, Germany
CollaboratorOTHER
BG Trauma Center Ludwigshafen
CollaboratorOTHER
Heidelberg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Fibromyalgia meeting ACR-criteria * Diagnosis of chronic back pain * Pain duration exceeding 3 months * Age between 18 and 70 years * The patient has been informed about the study, understood the information and signed the informed consent form

Exclusion criteria

* Tumors, fractures and heavy osteoporosis * Secondary back pain at arthrosis or degenerative scoliosis * Radicular back pain * Other pain syndrome is main problem * Opiate medication \> 60mg morphine per diem * Addiction (drugs, alcohol, medicaments) * Cardiac insufficiency \> NYHA II * Exercise induced dyspnea, Angina pectoris A detailed version of

Design outcomes

Primary

MeasureTime frame
Impairment by pain

Secondary

MeasureTime frame
physical function and emotional state assessed by questionnaires
number of serious adverse events
Pain intensity
subjective rating of therapy effectiveness
therapy satisfaction rated by patient
subjective rating of improvement by therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026